Cardiovascular Radiology Unit, Cardio-Thoracic-Vascular Department, University Hospital S. Orsola, Via Massarenti 9, 40128 Bologna, Italy.
Cardiovasc Intervent Radiol. 2011 Dec;34(6):1137-42. doi: 10.1007/s00270-011-0101-6. Epub 2011 Feb 3.
The overall survival of patients with thoracic aortic aneurysm (TAA) has improved significantly in the past few years. Endovascular treatment, proposed as an alternative to surgery, has been considered a therapeutic innovation because of its low degree of invasiveness, which allows the treatment of even high-surgical risk patients with limited complications and mortality. A major limitation is the lack of adequate evidence regarding long-term benefit and durability because follow-up has been limited to just a few years even in the largest series. The combination of endovascular exclusion with visceral branch revascularization for the treatment of thoraco-abdominal aortic aneurysms involving the visceral aorta has also been attempted. As an alternative, endografts with branches represent a technological evolution that allows treatment of complex anatomy. Even if only small numbers of patients and short follow-up are available, this technical approach, which has with limited mortality (<10%) and paraplegia rates, to expand endovascular treatment to TAA seems feasible. With improved capability to recognize proper anatomy and select clinical candidates, the choice of endovascular stent-graft placement may offer a strategy to optimize management and improve prognosis.
近年来,胸主动脉瘤(TAA)患者的总体生存率有了显著提高。血管内治疗因其微创性而被认为是一种治疗创新,可以治疗即使是手术风险较高的患者,并发症和死亡率都较低。主要限制因素是缺乏长期获益和耐久性的充分证据,因为即使在最大的系列中,随访也仅局限于几年。对于涉及内脏主动脉的胸腹主动脉瘤,血管内隔绝术联合内脏分支血运重建也已尝试应用。作为替代方法,带分支的血管内移植物代表了一种技术进步,它可以治疗复杂的解剖结构。尽管只有少数患者和短期随访,但这种技术方法的死亡率(<10%)和截瘫率都较低,似乎可以将血管内治疗扩展到 TAA。随着对适当解剖结构的识别能力和临床候选者的选择能力的提高,血管内支架移植物的放置选择可能提供了一种优化管理和改善预后的策略。